Artiva Biotherapeutics, INC Form 4 insider transactions
NASDAQ
Form 4: GC Corp. and GC Cell Corp. Report Changes in Ownership of Artiva Biotherapeutics Following IPO
GC Corp. and GC Cell Corp. report changes in beneficial ownership of Artiva Biotherapeutics common stock following the company's initial public offering.
NASDAQ
Form 4: Artiva Biotherapeutics Insider Filing: GC Corp and GC Cell Increase Common Stock Holdings Post-IPO
Yong-Jun Huh, as a director and related to significant shareholders GC Corp and GC Cell Corporation, reports transactions related to the conversion of preferred stock and SAFE agreements into common stock following Artiva Biotherapeutics' IPO.
NASDAQ
CEO Fred Aslan reports the acquisition of restricted stock units and stock options in Artiva Biotherapeutics.